Strategic Licensing Vaxinano's Stellar-NP adjuvant-free vaccine platform enables stable, rapid-to-deploy vaccines against hard-to-treat pathogens, creating opportunities for license deals with larger pharma, vaccine developers, or CMOs seeking a ready-to-translate delivery system.

Veterinary Expansion The Canine Leishmaniasis publication signals a path into veterinary vaccines; consider joint development or licensing of the Stellar-NP platform for animal health, diversifying revenue beyond human vaccines.

Partnership Momentum Ongoing collaboration with StaniPharm for vaccine delivery system development and production demonstrates a viable co development model; target additional CMOs and contract manufacturers to license the tech or run multi year development programs.

Funding Advantage Recent financing and ongoing fundraising position the company to pursue external collaborations with public and philanthropic partners; explore EU Horizon Europe, national grants, and public private partnerships to finance co development and scale up.

Outbreak Readiness The platform's rapid deployment and broad pathogen coverage appeal to public health agencies and NGOs seeking outbreak-ready vaccines; position Vaxinano as a preferred partner for rapid vaccine development and government contracts.